Clinical trials
PET/CT clinical trials
Below are recruiting pet/ct clinical trials, each written for real people, not researchers. We’re tracking 362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04272658Recruiting
Whole-body PET/CT scan during immunotherapy for melanoma
This trial studies how a whole-body PET/CT scan (using a radioactive sugar called FDG) can better track metastatic melanoma in people receiving immune therapy. It may help doctors understand tumor response to medications like nivolumab or pembrolizumab.
Brest, FinistereAges 18 years+ - NCT04275453RecruitingPhase 1/Phase 2
Test diet vs ketone drinks to reach ketosis safely
This early-stage study compares how quickly and effectively a low-carbohydrate diet versus taking ketone supplements helps the heart use less sugar (measured with PET/CT scans). It also looks at how long it takes to reach a “ketosis” state, which may be helpful for metabolic health.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04362644RecruitingPhase 1
Imaging agent study for idiopathic pulmonary fibrosis lung scarring
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Birmingham, AlabamaAges 40–85 - NCT04416165Recruiting
FDG versus FAPI PET scans for different cancers
This study compares two types of PET/CT scans—one that uses FDG and one that uses FAPI—to help doctors see and evaluate cancer in different situations. It may help improve how well scans detect tumors and guide care, though it requires getting both scans scheduled.
Xiamen, FujianAges 18–90 - NCT04451551Recruiting
PET/CT scan study for reduced blood flow in the heart
This study uses a special PET/CT scan that shows how well blood reaches your heart muscle. It may help doctors better assess suspected or known reduced blood flow (ischemic heart disease).
Aarhus, Aarhus NAges 18 years+ - NCT04522622RecruitingPhase 4
Teriparatide for low bone turnover in advanced kidney disease
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
AalborgAges 18–120 - NCT04546126RecruitingEarly Phase 1
PET scan study tracking cholesterol movement in your body
This early study uses a special PET scan dye to see how cholesterol moves through the body. It is testing how the imaging works in healthy people and in people with adrenal gland hormone secretion problems, to better understand cholesterol handling.
Ann Arbor, MichiganAges 18 years+ - NCT04596670RecruitingEarly Phase 1
Test PET/CT imaging using a cancer-targeting tracer
This early-phase trial uses a special PET/CT scan tracer called 68Ga-ICAM-1pep to help doctors find and stage cancers. You may be able to join if you have (or are suspected to have) certain cancers and can safely complete the scan steps.
Beijing, Beijing MunicipalityAges 18–80 - NCT04629326Recruiting
Imaging scan that targets PD-L1 in digestive cancer
This study tests an imaging method that looks for PD-L1 (a protein linked to some cancers) in solid tumors, including gastrointestinal cancers. It may help doctors better see where PD-L1 is in the body using a scan.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04668872Recruiting
Biopsy after liver radiation to see tumor cell changes
This trial gives radiation to liver tumors and then takes a small tissue sample (biopsy) to look for changes in the cancer cells after treatment. The goal is to learn what the radiation is doing inside the tumor, which may help improve future treatments.
New York, New YorkAges 18 years+ - NCT04700332RecruitingPhase 2
Test of PyL PET/CT for high-risk or returning prostate cancer
This Phase 2 study checks how well a scan called PyL PET/CT can help find prostate cancer that is high-risk or has come back by blood test. The goal is to improve how doctors detect spread and guide the next treatment steps.
Irvine, CaliforniaAges 18 years+ - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT04813705RecruitingPhase 2
PET/CT-guided lower-dose radiation for nasopharyngeal cancer
This Phase 2 study tests whether using a special scan (PET/CT) to guide radiation can safely reduce the radiation dose for people with nasopharyngeal cancer. It may help lessen side effects while still treating the cancer effectively.
Taizhou, ZhejiangAges 18–80 - NCT04846933Recruiting
Testing extra scans and data to guide ovarian cancer treatment
This trial collects information from people with suspected ovarian cancer and uses it to improve diagnosis and help predict which treatments may work. It may also look for targeted options, based on scan and medical data results.
TurkuAges 18 years+ - NCT04847505RecruitingPhase 3
Testing 68Ga-DOTA-TATE PET/CT scans for neuroendocrine tumors
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
Montreal, QuebecAges Any age - NCT04951817Recruiting
PSMA PET/CT scan to assess Ra-223 treatment in advanced prostate cancer
This trial studies whether a special whole-body scan (PSMA PET/CT) can help assess how well Ra-223 (a targeted treatment) may work in men with advanced prostate cancer that has spread to the bones. It may help doctors choose and plan Ra-223 treatment more effectively.
Taoyuan CityAges 40–85 - NCT04989959RecruitingPhase 1
PET/CT scan test in kidney cancer and related conditions
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
Dallas, TexasAges 18 years+ - NCT05069220RecruitingEarly Phase 1
PET/CT scan to study neural crest tumors
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
Beijing, DongchengAges 1–80 - NCT05137119RecruitingPhase 4
Adaptive study of treatments for staph bloodstream infection
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
Houston, TexasAges Any age - NCT05172310RecruitingPhase 1
PET scan study using a new tracer for solid tumors
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
StockholmAges 19 years+ - NCT05276037Recruiting
PET/CT scan to guide liver transplant decisions in liver cancer
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
AntwerpAges 18–80 - NCT05324332Recruiting
Two scans to study prostate cancer in the same group
This trial looks at prostate cancer patients who have not started treatment yet and have two different PET/CT scans close together. It may help doctors compare how these scans show prostate cancer in the body.
Beijing, Beijing MunicipalityAges 18–90 - NCT05374278RecruitingPhase 1/Phase 2
PET scan test for a dementia brain tracer
This early-phase study tests a new PET scan tracer that targets a brain chemical transport system involved in dementia. It aims to see if the tracer can safely and clearly show brain changes, which could help future dementia diagnosis or tracking.
San Francisco, CaliforniaAges 40–75 - NCT05442151Recruiting
Scan to see cancer-fighting cells using a special PET tracer
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
Suita, OsakaAges Any age
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pet/ct?
- Yes. Clin2 currently lists 362 recruiting pet/ct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pet/ct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pet/ct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.